AVRO - AVROBIO, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
AVRO price evolution
AVRO
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $98.3 | $106.13 | $124.97 | $72.33 |
| Short term investments | ||||
| Net receivables | $0.27 | $0.27 | ||
| Inventory | ||||
| Total current assets | $100.26 | $109.17 | $128.84 | $77.25 |
| Long term investments | $0.4 | $0.4 | $0.4 | $0.28 |
| Property, plant & equipment | $0.43 | $0.91 | $4.55 | $5.43 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.83 | $1.35 | $4.99 | $5.75 |
| Total investments | $0.4 | $0.4 | $0.4 | $0.28 |
| Total assets | $101.09 | $110.52 | $133.84 | $83 |
| Current liabilities | ||||
| Accounts payable | $0.03 | $0.91 | $1.07 | $0.59 |
| Deferred revenue | ||||
| Short long term debt | $0.88 | $1.65 | $2.25 | $2.63 |
| Total current liabilities | $6.35 | $7.56 | $11.66 | $14.3 |
| Long term debt | $0.1 | $0.13 | $15.71 | |
| Total noncurrent liabilities | $0.1 | $0.13 | $15.71 | |
| Total debt | $0.88 | $1.75 | $2.38 | $18.34 |
| Total liabilities | $6.35 | $7.66 | $11.8 | $30.01 |
| Shareholders' equity | ||||
| Retained earnings | -$477.27 | -$468.49 | -$446.91 | -$514.39 |
| Other shareholder equity | ||||
| Total shareholder equity | $94.74 | $102.86 | $122.04 | $53 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $98.3 | $92.85 | $190.06 | $260.17 |
| Short term investments | ||||
| Net receivables | $0.27 | $2.7 | $2.6 | |
| Inventory | ||||
| Total current assets | $100.26 | $99.96 | $199.15 | $267.24 |
| Long term investments | $0.4 | |||
| Property, plant & equipment | $0.43 | $3.95 | $4.13 | $3.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.83 | $3.99 | $4.69 | $3.99 |
| Total investments | $0.4 | |||
| Total assets | $101.09 | $103.95 | $203.84 | $271.23 |
| Current liabilities | ||||
| Accounts payable | $0.03 | $0.38 | $3.49 | $2.68 |
| Deferred revenue | ||||
| Short long term debt | $0.88 | $1 | ||
| Total current liabilities | $6.35 | $13.12 | $19.39 | $16.61 |
| Long term debt | $15.28 | $14.95 | ||
| Total noncurrent liabilities | $15.46 | $14.97 | $0.28 | |
| Total debt | $0.88 | $16.46 | $14.95 | |
| Total liabilities | $6.35 | $28.58 | $34.36 | $16.89 |
| Shareholders' equity | ||||
| Retained earnings | -$477.27 | -$489.43 | -$383.54 | -$264.42 |
| Other shareholder equity | $75.37 | $169.48 | ||
| Total shareholder equity | $94.74 | $75.37 | $169.48 | $254.34 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $4.39 | $14.83 | $11.15 | |
| Selling, general & administrative | $5.24 | $6.26 | $4.58 | |
| Total operating expenses | $9.66 | $22.93 | -$68.01 | |
| Operating income | -$9.66 | -$22.93 | $68.01 | |
| Income from continuing operations | ||||
| EBIT | -$9.67 | -$22.98 | $67.97 | |
| Income tax expense | $0.38 | |||
| Interest expense | -$1.26 | -$1.41 | $0.49 | |
| Net income | ||||
| Net income | -$8.79 | -$21.58 | $67.48 | |
| Income (for common shares) | -$8.79 | -$21.58 | $67.48 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $47.7 | $72.19 | $83.11 | $87.24 |
| Selling, general & administrative | $23.97 | $33.25 | $35.73 | $32.99 |
| Total operating expenses | -$10.19 | $105.43 | $118.84 | $120.23 |
| Operating income | $10.19 | -$105.43 | -$118.84 | -$120.23 |
| Income from continuing operations | ||||
| EBIT | $10.11 | -$105.59 | -$119.35 | -$119.71 |
| Income tax expense | $0.38 | |||
| Interest expense | -$2.42 | $0.3 | -$0.22 | |
| Net income | ||||
| Net income | $12.16 | -$105.89 | -$119.13 | -$119.71 |
| Income (for common shares) | $12.16 | -$105.89 | -$119.13 | -$119.71 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$8.79 | -$21.58 | $67.48 | -$24.96 |
| Operating activities | ||||
| Depreciation | $0.32 | $0.41 | $0.88 | $0.92 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.61 | $2.22 | $1.53 | $2.53 |
| Total cash flows from operations | -$8.03 | -$20.22 | -$14.65 | -$20.28 |
| Investing activities | ||||
| Capital expenditures | $0.15 | $1.2 | -$0.01 | |
| Investments | ||||
| Total cash flows from investing | $0.15 | $1.2 | $83.74 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.06 | $0.18 | $0.03 | $0.06 |
| Net borrowings | -$16.35 | |||
| Total cash flows from financing | $0.06 | $0.18 | -$16.32 | $0.06 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$7.82 | -$18.85 | $52.76 | -$20.24 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $12.16 | -$105.89 | -$119.13 | -$119.71 |
| Operating activities | ||||
| Depreciation | $2.53 | $4.17 | $1.4 | $1.21 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.89 | $11.52 | $18.58 | $15.63 |
| Total cash flows from operations | -$63.19 | -$97.21 | -$98.03 | -$98.8 |
| Investing activities | ||||
| Capital expenditures | $1.34 | -$0.27 | -$2.46 | -$1.18 |
| Investments | ||||
| Total cash flows from investing | $85.08 | -$0.27 | -$2.46 | -$1.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.32 | $0.26 | $15.47 | $172.62 |
| Net borrowings | -$16.35 | $14.9 | ||
| Total cash flows from financing | -$16.03 | $0.26 | $30.37 | $172.62 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $5.86 | -$97.21 | -$70.11 | $72.64 |
News
Fundamentals
| Market cap | $53.14M |
|---|---|
| Enterprise value | -$44.29M |
| Shares outstanding | 44.65M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.56 |
| Book/Share | 2.12 |
| Cash/Share | 2.20 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.07 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 15.78 |
| Quick ratio | 15.78 |